etoposide has been researched along with Hormone-Dependent Neoplasms in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 12 (60.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antona, AD; Cipolla, C; Ciulla, A; Graceffa, G; Grillo, A; Locurto, P; Martorana, S; Vieni, S | 1 |
| Beuzeboc, P; Culine, S; Deplanque, G; Droz, JP; Fargeot, P; Ferlay, C; Fléchon, A; Gravis, G; Joly, F; Oudard, S; Perol, D; Pouessel, D; Priou, F; Zanetta, S | 1 |
| Akudugu, JM; Bohm, L; Serafin, AM | 1 |
| Dimtchev, A; Dritschilo, A; Jung, M; Rosenthal, D; Smulson, M; Soldatenkov, V; Trofimova, I | 1 |
| Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J | 1 |
| Asakuma, J; Asano, T; Hayakawa, M; Nanus, DM; Sumitomo, M | 1 |
| Du, W; Fontana, J; Hussain, M; Vaishampayan, U | 1 |
| Garrett, MD; Mantoni, TS; Reid, G | 1 |
| Bogdanos, J; Dimopoulos, P; Dimopoulos, T; Halapas, A; Karamanolakis, D; Katopodis, H; Koutsilieris, M; Lembessis, P; Milathianakis, C; Papageorgiou, E; Pissimissis, N; Pitulis, N; Sourla, A; Tenta, R | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Dutt, SS; Gao, AC; Lee, SO; Liao, H; Nadiminty, N; Pinder, E | 1 |
| Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC | 1 |
| Alimirah, F; Chen, J; Choubey, D; Ho, SM; Panchanathan, R; Zhang, X | 1 |
| Dive, C; Hickman, JA; Morris, ID; Wakeling, AE; Wilson, JW | 1 |
| Buzdar, AU; Dicke, KA; Dunphy, FR; Fornoff, JE; Hortobagyi, GN; Huan, SD; Spitzer, G; Yau, JC | 1 |
| Alken, P; Köhrmann, KU; Kreukler, C; Nebe, T; Siegsmund, MJ; Steidler, A | 1 |
| Pienta, KJ; Smith, DC | 1 |
| Baly, D; Beryt, M; Coombs, D; Hsu, S; Kabbinavar, F; Lewis, G; Pegram, M; Pietras, R; Slamon, D; Sliwkowski, M | 1 |
| Ericson, SG; Fortney, J; Gibson, LF; Landreth, KS; Lynch, JP; Magro, G | 1 |
| Brady, HP; Coffey, RN; Fitzpatrick, JM; Gibbons, NB; Watson, RW | 1 |
3 review(s) available for etoposide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Primary neuroendocrine carcinoma of the breast A single Center experience and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Estrogens; Etoposide; Female; Humans; Mastectomy; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Receptors, Steroid; Retrospective Studies; Sentinel Lymph Node Biopsy; Tamoxifen | 2016 |
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Estramustine; Etoposide; Gonadotropin-Releasing Hormone; Growth Substances; Humans; Leuprolide; Male; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Orchiectomy; Osteoblasts; Osteoclasts; Paracrine Communication; Peptides, Cyclic; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Salvage Therapy; Somatostatin; Survival Analysis; Triptorelin Pamoate | 2006 |
Paclitaxel in the treatment of hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Estramustine; Etoposide; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms | 1999 |
5 trial(s) available for etoposide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Differentiation; Chromogranin A; Disease-Free Survival; Etoposide; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Neuroendocrine Cells; Orchiectomy; Prospective Studies; Prostatic Neoplasms | 2011 |
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Survival Rate | 2004 |
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Risk Factors | 1994 |
12 other study(ies) available for etoposide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
Topics: Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Gene Expression Regulation; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2002 |
Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; DNA Damage; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Genetic Therapy; Humans; Male; Metribolone; Neoplasms, Hormone-Dependent; Plasmids; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Structure, Tertiary; Testosterone Congeners; Transfection; Tumor Cells, Cultured | 2002 |
Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase.
Topics: Androgens; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Cells, Cultured; Drug Resistance, Neoplasm; Epithelial Cells; Etoposide; Humans; Male; Mitochondria; Neoplasms, Hormone-Dependent; Neprilysin; Organophosphonates; Phenylalanine; Prostate; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C-delta; Recombinant Proteins | 2004 |
Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Chromatin Immunoprecipitation; Cisplatin; Dihydrotestosterone; Etoposide; Humans; Ligands; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Subcellular Fractions; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Topics: Androgen Antagonists; Androgens; Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Etoposide; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; STAT3 Transcription Factor | 2007 |
Expression of androgen receptor is negatively regulated by p53.
Topics: 5' Untranslated Regions; Adenocarcinoma; Androgens; Bone Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Consensus Sequence; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Male; Neoplasms, Hormone-Dependent; Osteosarcoma; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Transfection; Tumor Suppressor Protein p53 | 2007 |
MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Death; Cell Division; Cell Survival; DNA Damage; DNA, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Etoposide; Fulvestrant; Humans; Mechlorethamine; Neoplasms, Hormone-Dependent; Tumor Cells, Cultured | 1995 |
Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
Topics: Androgens; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorescent Dyes; Genes, MDR; Male; Methotrexate; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Rhodamine 123; Rhodamines; Tumor Cells, Cultured; Verapamil; Vinblastine | 1997 |
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Cycle; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Protein Processing, Post-Translational; Receptor, ErbB-2; Recombinant Proteins; Thiotepa; Topoisomerase II Inhibitors; Transplantation, Heterologous; Trastuzumab; Treatment Outcome; Vinblastine | 1999 |
Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Estrogens; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1999 |
Heat-shock proteins inhibit induction of prostate cancer cell apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Blotting, Western; Cycloheximide; Etoposide; Glutathione; Glutathione Transferase; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Kinetics; Male; Maleates; Molecular Chaperones; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nucleic Acid Synthesis Inhibitors; Prostatic Neoplasms; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Tumor Cells, Cultured | 2000 |